作者
Alissa Hendricks-Wenger, Kenneth N Aycock, Margaret A Nagai-Singer, Sheryl Coutermarsh-Ott, Melvin F Lorenzo, Jessica Gannon, Kyungjun Uh, Kayla Farrell, Natalie Beitel-White, Rebecca M Brock, Alexander Simon, Holly A Morrison, Joanne Tuohy, Sherrie Clark-Deener, Eli Vlaisavljevich, Rafael V Davalos, Kiho Lee, Irving C Allen
发表日期
2021/4/7
期刊
Scientific reports
卷号
11
期号
1
页码范围
1-14
出版商
Nature Publishing Group
简介
New therapies to treat pancreatic cancer are direly needed. However, efficacious interventions lack a strong preclinical model that can recapitulate patients’ anatomy and physiology. Likewise, the availability of human primary malignant tissue for ex vivo studies is limited. These are significant limitations in the biomedical device field. We have developed RAG2/IL2RG deficient pigs using CRISPR/Cas9 as a large animal model with the novel application of cancer xenograft studies of human pancreatic adenocarcinoma. In this proof-of-concept study, these pigs were successfully generated using on-demand genetic modifications in embryos, circumventing the need for breeding and husbandry. Human Panc01 cells injected subcutaneously into the ears of RAG2/IL2RG deficient pigs demonstrated 100% engraftment with growth rates similar to those typically observed in mouse models. Histopathology revealed no …
学术搜索中的文章
A Hendricks-Wenger, KN Aycock, MA Nagai-Singer… - Scientific reports, 2021